
    
      The primary objective of these studies is to assess the efficacy and safety of allogeneic
      pancreatic islet transplantation in the treatment of type I diabetes mellitus. A secondary
      study objective is to evaluate the efficacy of various immunosuppressive protocols and agents
      in preventing autoimmune destruction and rejection of allogeneic islet transplants. A
      tertiary objective is to determine the safety and efficacy of allogeneic pancreatic islet
      transplantation in patients who have received another organ transplant such as a kidney or
      liver.
    
  